{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:49:16Z","timestamp":1787986156079,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01104-y","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:36:40Z","timestamp":1752136600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Doxorubicin Stability-indicating Method and its Main Degradation Products In vitro Toxicity"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5811-0749","authenticated-orcid":false,"given":"Mariah","family":"de Almeida Ultramari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-5601","authenticated-orcid":false,"given":"Ariane","family":"Rivellis Julio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7024-6899","authenticated-orcid":false,"given":"Larissa","family":"Souza Passos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4127-8012","authenticated-orcid":false,"given":"Alexander","family":"Ossanes de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4860-7543","authenticated-orcid":false,"given":"N\u00fabia","family":"Pereira da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-4754","authenticated-orcid":false,"given":"Paloma Nathane","family":"Nunes de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7614-3014","authenticated-orcid":false,"given":"Ernani","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"1104_CR1","doi-asserted-by":"publisher","first-page":"119527","DOI":"10.1016\/j.lfs.2021.119527","volume":"278","author":"S Sritharan","year":"2021","unstructured":"Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 2021;278:119527. https:\/\/doi.org\/10.1016\/j.lfs.2021.119527.","journal-title":"Life Sci"},{"key":"1104_CR2","doi-asserted-by":"publisher","unstructured":"Ajaykumar C. Overview on the Side Effects of Doxorubicin. In: Arnouk H, Hassan BAR, editors. Advances in Precision Medicine Oncology. IntechOpen; 2020. https:\/\/doi.org\/10.5772\/intechopen.94896","DOI":"10.5772\/intechopen.94896"},{"key":"1104_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2174\/1573394716666191216114950","volume":"16","author":"M Vyas","year":"2020","unstructured":"Vyas M, Simbo DA, Mursalin M, Mishra V, Bashary R, Khatik GL. Drug Delivery Approaches for Doxorubicin in the Management of Cancers. Curr Cancer Ther Rev. 2020;16:320\u201331. https:\/\/doi.org\/10.2174\/1573394716666191216114950.","journal-title":"Curr Cancer Ther Rev"},{"key":"1104_CR4","unstructured":"Brunton LL, Chabner BA, Knollmann BC. As bases farmacol\u00f3gicas da terap\u00eautica de Goodman & Gilman. 3. ed. Porto Alegre, Brazil: AMGH, 2019. ISBN 9788580556148."},{"key":"1104_CR5","doi-asserted-by":"publisher","DOI":"10.3109\/9781439801802","volume-title":"Pharmaceutical stress testing: predicting drug degradation","author":"SW Baertschi","year":"2016","unstructured":"Baertschi SW, Alsante KM, Reed RA. Pharmaceutical stress testing: predicting drug degradation. Boca Raton (FL): CRC Press; 2016."},{"key":"1104_CR6","unstructured":"Rang R, Ritter JM, Flower RJ, Henderson G. Rang & dale farmacologia. Rio de Janeiro, Brazil: Elsevier Brazil; 2015."},{"key":"1104_CR7","unstructured":"World Health Organization. Quality assurance of pharmaceuticals: a compendium of guidelines and related materials. Good manufacturing practices and inspection. World Health Organization; 2007."},{"key":"1104_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0731-7085(95)01573-6","volume":"14","author":"JC Berridge","year":"1995","unstructured":"Berridge JC. Impurities in drug substances and drug products: new approaches to quantification and qualification. J Pharm Biomed Anal. 1995;14:7\u201312. https:\/\/doi.org\/10.1016\/0731-7085(95)01573-6.","journal-title":"J Pharm Biomed Anal"},{"key":"1104_CR9","doi-asserted-by":"publisher","first-page":"119018","DOI":"10.1016\/j.ijpharm.2019.119018","volume":"576","author":"D Pokar","year":"2020","unstructured":"Pokar D, Rajput N, Sengupta P. Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products. Int J Pharm. 2020;576:119018. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.119018.","journal-title":"Int J Pharm"},{"key":"1104_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.addr.2006.10.005","volume":"59","author":"MD Argentine","year":"2007","unstructured":"Argentine MD, Owens PK, Olsen BA. Strategies for the investigation and control of process-related impurities in drug substances. Adv Drug Deliv Rev. 2007;59:12\u201328. https:\/\/doi.org\/10.1016\/j.addr.2006.10.005.","journal-title":"Adv Drug Deliv Rev"},{"key":"1104_CR11","unstructured":"ICH H. Impurities in new drug products. Q3B (R2), current step. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH, Geneva. 2006."},{"key":"1104_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jpha.2015.05.003","volume":"5","author":"D Kaushik","year":"2015","unstructured":"Kaushik D, Bansal G. Four new degradation products of doxorubicin: An application of forced degradation study and hyphenated chromatographic techniques. J Pharm Anal. 2015;5:285\u201395. https:\/\/doi.org\/10.1016\/j.jpha.2015.05.003.","journal-title":"J Pharm Anal."},{"key":"1104_CR13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/jps.2600791016","volume":"79","author":"R Wada","year":"1990","unstructured":"Wada R, Hyon S-H, Ikada Y. Lactic Acid Oligomer Microspheres Containing Hydrophilic Drugs. J Pharm Sci. 1990;79:919\u201324. https:\/\/doi.org\/10.1002\/jps.2600791016.","journal-title":"J Pharm Sci"},{"key":"1104_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/0022-2313(75)90003-4","volume":"10","author":"MM Martin","year":"1975","unstructured":"Martin MM, Lindqvist L. The pH dependence of fluorescein fluorescence. J Lumin. 1975;10:381\u201390. https:\/\/doi.org\/10.1016\/0022-2313(75)90003-4.","journal-title":"J Lumin"},{"key":"1104_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1751-1097.1995.tb08619.x","volume":"61","author":"S Dhami","year":"1995","unstructured":"Dhami S, de Mello AJ, Rumbles G, Bishop SM, Phillips D, Beeby A. Phthalocyanine fluorescence at high concentration: dimers or reabsorption effect? Photochem Photobiol. 1995;61:341\u20136. https:\/\/doi.org\/10.1111\/j.1751-1097.1995.tb08619.x.","journal-title":"Photochem Photobiol"},{"key":"1104_CR16","unstructured":"BRASIL. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Resolu\u00e7\u00e3o no 166, de 24 de julho de 2017. Disp\u00f5e sobre a valida\u00e7\u00e3o de m\u00e9todos anal\u00edticos e d\u00e1 outras provid\u00eancias. https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/anvisa\/2017\/rdc0166_24_07_2017.pdf. Acessed 26 May 2025."},{"key":"1104_CR17","unstructured":"BRASIL. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Resolu\u00e7\u00e3o da Diretoria Colegiada n\u00b0 53\/2015. Estabelece par\u00e2metros para a notifica\u00e7\u00e3o, identifica\u00e7\u00e3o e qualifica\u00e7\u00e3o de produtos de degrada\u00e7\u00e3o em medicamentos com subst\u00e2ncias ativas sint\u00e9ticas e semissint\u00e9ticas, classificados como novos, gen\u00e9ricos e similares, e d\u00e1 outras provid\u00eancias. https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/anvisa\/2015\/rdc0053_04_12_2015.pdf. Acessed 26 May 2025."},{"key":"1104_CR18","unstructured":"Silverstein RM, Webster FX, Kiemle DJ. Spectrometric Identification of Organic Compounds. 7th ed. Hoboken, NJ: John Wiley & Sons. 2005."},{"key":"1104_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jpba.2008.12.029","volume":"50","author":"J Cielecka-Piontek","year":"2009","unstructured":"Cielecka-Piontek J, Jeli\u0144ska A, Zaj\u0105c M, Sobczak M, Bartold A, Oszczapowicz I. A comparison of the stability of doxorubicin and daunorubicin in solid state. J Pharm Biomed Anal. 2009;50:576\u20139. https:\/\/doi.org\/10.1016\/j.jpba.2008.12.029.","journal-title":"J Pharm Biomed Anal"},{"key":"1104_CR20","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1039\/C2RA01221A","volume":"2","author":"R Anand","year":"2012","unstructured":"Anand R, Ottani S, Manoli F, Manet I, Monti S. A close-up on doxorubicin binding to \u03b3-cyclodextrin: an elucidating spectroscopic, photophysical and conformational study. RSC Adv. 2012;2:2346\u201357. https:\/\/doi.org\/10.1039\/C2RA01221A.","journal-title":"RSC Adv"},{"key":"1104_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1023\/a:1018869818282","volume":"16","author":"S Bandak","year":"1999","unstructured":"Bandak S, Ramu A, Barenholz Y, Gabizon A. Reduced UV-induced degradation of doxorubicin encapsulated in polyethyleneglycol-coated liposomes. Pharm Res. 1999;16:841\u20136. https:\/\/doi.org\/10.1023\/a:1018869818282.","journal-title":"Pharm Res"},{"key":"1104_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/med.2610130404","volume":"13","author":"Y Barenholz","year":"1993","unstructured":"Barenholz Y, Amselem S, Goren D, Cohen R, Gelvan D, Samuni A, et al. Stability of liposomal doxorubicin formulations: problems and prospects. Med Res Rev. 1993;13:449\u201391. https:\/\/doi.org\/10.1002\/med.2610130404.","journal-title":"Med Res Rev"},{"key":"1104_CR23","doi-asserted-by":"crossref","unstructured":"Lakowicz JR. Principles of fluorescence spectroscopy. 3rd edn. New York. 2006","DOI":"10.1007\/978-0-387-46312-4"},{"key":"1104_CR24","unstructured":"Snyder LR, Kirkland JJ, Dolan JW. Introduction to modern liquid chromatography. 3rd ed. Hoboken, NJ: John Wiley & Sons, United States 2011."},{"key":"1104_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","volume":"4","author":"M Blessy","year":"2014","unstructured":"Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs-A review. J Pharm Anal. 2014;4:159\u201365. https:\/\/doi.org\/10.1016\/j.jpha.2013.09.003.","journal-title":"J Pharm Anal"},{"key":"1104_CR26","doi-asserted-by":"publisher","unstructured":"Maheshwari R, Todke P, Soni N, Raval N, Deb PK, Amarji B, et al. Stability and degradation studies for drug and drug product. Dosage Form Design Considerations, Elsevier; 2018;i:225\u201357. https:\/\/doi.org\/10.1016\/B978-0-12-814423-7.00007-1","DOI":"10.1016\/B978-0-12-814423-7.00007-1"},{"key":"1104_CR27","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1016\/j.xphs.2023.09.003","volume":"112","author":"T Zelesky","year":"2023","unstructured":"Zelesky T, Baertschi SW, Foti C, Allain LR, Hostyn S, Franca JR, et al. Pharmaceutical forced degradation (stress testing) endpoints: A scientific rationale and industry perspective. J Pharm Sci. 2023;112:2948\u201364. https:\/\/doi.org\/10.1016\/j.xphs.2023.09.003.","journal-title":"J Pharm Sci"},{"key":"1104_CR28","first-page":"1","volume":"4","author":"S Singh","year":"2000","unstructured":"Singh S, Bakshi M. Stress test to determine inherent stability of drugs. Pharm Technol. 2000;4:1\u201314.","journal-title":"Pharm Technol"},{"key":"1104_CR29","volume-title":"Guide for Students of Organic Chemistry","author":"DL Pavia","year":"2001","unstructured":"Pavia DL, Lampman GM, Kriz GS. Guide for Students of Organic Chemistry. 3rd ed. London: Brooks\/Cole, United Kingdom; 2001.","edition":"3"},{"key":"1104_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1023\/A:1016274825322","volume":"12","author":"NP Barbour","year":"1995","unstructured":"Barbour NP, Paborji M, Alexander TC, Coppola WP, Bogardus JB. Stabilization of Chimeric BR96-Doxorubicin Immunoconjugate. Pharm Res. 1995;12:215\u201322. https:\/\/doi.org\/10.1023\/A:1016274825322.","journal-title":"Pharm Res"},{"key":"1104_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0378-5173(83)90115-1","volume":"14","author":"K Wassermann","year":"1983","unstructured":"Wassermann K, Bundgaard H. Kinetics of the acid-catalyzed hydrolysis of doxorubicin. Int J Pharm. 1983;14:73\u20138. https:\/\/doi.org\/10.1016\/0378-5173(83)90115-1.","journal-title":"Int J Pharm"},{"key":"1104_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1021\/js9702067","volume":"87","author":"DD Wirth","year":"1998","unstructured":"Wirth DD, Baertschi SW, Johnson RA, Maple SR, Miller MS, Hallenbeck DK, et al. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. J Pharm Sci. 1998;87:31\u20139. https:\/\/doi.org\/10.1021\/js9702067.","journal-title":"J Pharm Sci"},{"key":"1104_CR33","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3390\/foods10091998","volume":"10","author":"J Xiang","year":"2021","unstructured":"Xiang J, Liu F, Wang B, Chen L, Liu W, Tan S. A literature review on maillard reaction based on milk proteins and carbohydrates in food and pharmaceutical products: advantages, disadvantages, and avoidance strategies. Foods. 2021;10:1998. https:\/\/doi.org\/10.3390\/foods10091998.","journal-title":"Foods"},{"key":"1104_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/pharmaceutics14020325","volume":"14","author":"A Gabri\u010d","year":"2022","unstructured":"Gabri\u010d A, Hodnik \u017d, Pajk S. Oxidation of drugs during drug product development: problems and solutions. Pharmaceutics. 2022;14:325. https:\/\/doi.org\/10.3390\/pharmaceutics14020325.","journal-title":"Pharmaceutics"},{"key":"1104_CR35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jps.2600530726","volume":"53","author":"L Kennon","year":"1964","unstructured":"Kennon L. Use of models in determining chemical pharmaceutical stability. J Pharm Sci. 1964;53:815\u20138. https:\/\/doi.org\/10.1002\/jps.2600530726.","journal-title":"J Pharm Sci"},{"key":"1104_CR36","unstructured":"ICH. Q1B, Stability testing: photostability testing of new drug substances and products. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva. 1996."},{"key":"1104_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s002800050694","volume":"40","author":"L Bomgaars","year":"1997","unstructured":"Bomgaars L, Gunawardena S, Kelley SE, Ramu A. The inactivation of doxorubicin by long ultraviolet light. Cancer Chemother Pharmacol. 1997;40:506\u201312. https:\/\/doi.org\/10.1007\/s002800050694.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1104_CR38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.yrtph.2010.06.013","volume":"58","author":"MH Kleinman","year":"2010","unstructured":"Kleinman MH, Smith MD, Kurali E, Kleinpeter S, Jiang K, Zhang Y, et al. An evaluation of chemical photoreactivity and the relationship to phototoxicity. Regul Toxicol Pharmacol. 2010;58:224\u201332. https:\/\/doi.org\/10.1016\/j.yrtph.2010.06.013.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1104_CR39","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1897\/09-173.1","volume":"28","author":"MD Celiz","year":"2009","unstructured":"Celiz MD, Tso J, Aga DS. Pharmaceutical metabolites in the environment: analytical challenges and ecological risks. Environ Toxicol Chem. 2009;28:2473\u201384. https:\/\/doi.org\/10.1897\/09-173.1.","journal-title":"Environ Toxicol Chem"},{"key":"1104_CR40","doi-asserted-by":"publisher","first-page":"869332","DOI":"10.3389\/fmicb.2022.869332","volume":"13","author":"M Ort\u00fazar","year":"2022","unstructured":"Ort\u00fazar M, Esterhuizen M, Olic\u00f3n-Hern\u00e1ndez DR, Gonz\u00e1lez-L\u00f3pez J, Aranda E. Pharmaceutical pollution in aquatic environments: a concise review of environmental impacts and bioremediation systems. Front Microbiol. 2022;13:869332. https:\/\/doi.org\/10.3389\/fmicb.2022.869332.","journal-title":"Front Microbiol"},{"key":"1104_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55\u201363. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4.","journal-title":"J Immunol Methods"},{"key":"1104_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3109\/10408444.2013.808172","volume":"43","author":"EJ Calabrese","year":"2013","unstructured":"Calabrese EJ. Hormetic mechanisms. Crit Rev Toxicol. 2013;43:580\u2013606.\u00a0https:\/\/doi.org\/10.3109\/10408444.2013.808172.","journal-title":"Crit Rev Toxicol"},{"key":"1104_CR43","first-page":"487","volume":"70","author":"EN Dessypris","year":"1986","unstructured":"Dessypris EN, Brenner DE, Hande KR. Toxicity of doxorubicin metabolites to human marrow erythroid and myeloid progenitors in vitro. Cancer Treat Rep. 1986;70:487\u201390.","journal-title":"Cancer Treat Rep"},{"key":"1104_CR44","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s12032-010-9512-5","volume":"28","author":"Z Nurgalieva","year":"2011","unstructured":"Nurgalieva Z, Liu C-C, Du XL. Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer. Med Oncol. 2011;28:716\u201325. https:\/\/doi.org\/10.1007\/s12032-010-9512-5.","journal-title":"Med Oncol"},{"key":"1104_CR45","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.biocel.2012.06.010","volume":"44","author":"KN Bhinge","year":"2012","unstructured":"Bhinge KN, Gupta V, Hosain SB, Satyanarayanajois SD, Meyer SA, Blaylock B, Zhang Q, Liu Y. The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase. Int J Biochem Cell Biol. 2012;44:1770\u20138. https:\/\/doi.org\/10.1016\/j.biocel.2012.06.010.","journal-title":"Int J Biochem Cell Biol"},{"key":"1104_CR46","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/jnci\/djq361","volume":"102","author":"AM Calcagno","year":"2010","unstructured":"Calcagno AM, Salcido CD, Gillet J-P, Wu C-P, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst. 2010;102:1637\u201352. https:\/\/doi.org\/10.1093\/jnci\/djq361.","journal-title":"J Natl Cancer Inst"},{"key":"1104_CR47","doi-asserted-by":"publisher","unstructured":"Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella\/mammalian-microsome mutagenicity test. Mutat Res. 1975;31. https:\/\/doi.org\/10.1016\/0165-1161(75)90046-1.","DOI":"10.1016\/0165-1161(75)90046-1"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01104-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01104-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01104-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:24:14Z","timestamp":1757208254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01104-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1104"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01104-y","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"117"}}